Repurposing antihypertensive drugs for pain disorders: a drug-target mendelian randomization study

被引:0
|
作者
Du, Kai [1 ]
Li, Ao [1 ]
Zhang, Chen-Yu [1 ]
Li, Shu-Ming [2 ]
Chen, Ping [2 ]
机构
[1] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Pain Med, Beijing, Peoples R China
关键词
antihypertensive drug; hypertension; pain management; drug target mendelian randomization; drug repurposing; GENE-RELATED PEPTIDE; PRETREATMENT; INJECTION; ASSOCIATION; INSTRUMENTS; PROVIDES; ESMOLOL; BIAS;
D O I
10.3389/fphar.2024.1448319
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective Addressing the rising prevalence of pain disorders and limitations of current analgesics, our study explores repurposing antihypertensive drugs for pain management, inspired by the link between hypertension and pain. We leverage a drug-target Mendelian Randomization (MR) approach to explore their dual benefits and establish causal connections.Methods A comprehensive compilation of antihypertensive drug classes was undertaken through British National Formulary, with their target genes identified using the DrugBank database. Relevant single nucleotide polymorphisms (SNPs) associated with these targets were selected from published genomic studies on systolic blood pressure (SBP) as genetic instruments. These SNPs were validated through MR against acute coronary artery disease (CAD) to ensure genes not linked to CAD were excluded from acting as proxies for antihypertensive drugs. An MR analysis of 29 pain-related outcomes was conducted using the FinnGen R10 database employing the selected and validated genetic instruments. We utilized the Inverse Variance Weighted (IVW) method for primary analysis, applying Bonferroni correction to control type I error. IVW's multiplicative random effects (MRE) addressed heterogeneity, and MR-PRESSO managed pleiotropy, ensuring accurate causal inference.Results Our analysis differentiates strong and suggestive evidence in linking antihypertensive drugs to pain disorder risks. Strong evidence was found for adrenergic neuron blockers increasing migraine without aura risk, loop diuretics reducing panniculitis, and vasodilator antihypertensives lowering limb pain risk. Suggestive evidence suggests alpha-adrenoceptor blockers might increase migraine risk, while beta-adrenoceptor blockers could lower radiculopathy risk. Adrenergic neuron blockers also show a potential protective effect against coxarthrosis (hip osteoarthritis) and increased femgenpain risk (pain and other conditions related to female genital organs and menstrual cycle). Additionally, suggestive links were found between vasodilator antihypertensives and reduced radiculopathy risk, and both alpha-adrenoceptor blockers and renin inhibitors possibly decreasing dorsalgianas risk (unspecified dorsalgia). These findings highlight the intricate effects of antihypertensive drugs on pain disorders, underlining the need for further research.Conclusion The findings indicate that antihypertensive medications may exert varied effects on pain management, suggesting a repurposing potential for treating specific pain disorders. The results advocate for further research to confirm these associations and to explore underlying mechanisms, to optimize pain management practices.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Interpreting the Clinical Implications of Drug-Target Mendelian Randomization Studies COMMENT
    Ference, Brian A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (07) : 663 - 665
  • [22] The causal relationship between antihypertensive drugs and depression: a Mendelian randomization study of drug targets
    Yang, Zixian
    Li, Jinshuai
    Huang, Peichu
    Li, Zhichang
    He, Jianfeng
    Cai, Dongchun
    Lai, Yuzheng
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [23] Association of antihypertensive drug target genes with alzheimer's disease: a mendelian randomization study
    Zheng, He
    Chen, Chaolei
    Feng, Yingqing
    ALZHEIMERS RESEARCH & THERAPY, 2025, 17 (01)
  • [24] Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study
    Cai, Gexiang
    Liu, Jingjing
    Cai, Mengsi
    Shao, Lianyou
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [25] Lipid-lowering drugs affect lung cancer risk via sphingolipid metabolism: a drug-target Mendelian randomization study
    Li, Honglin
    Zhang, Lei
    Yang, Feiran
    Feng, Xiaoteng
    Fu, Rong
    Zhao, Ruohan
    Li, Xiurong
    Li, Huijie
    FRONTIERS IN GENETICS, 2023, 14
  • [26] Genetic correlation between genes targeted by lipid-lowering drugs and venous thromboembolism: A drug-target Mendelian randomization study
    Li, Min
    Duan, Hangyu
    Luo, Jinwen
    Tan, Yu
    Liu, Min
    Zhao, Xiaohan
    Shi, Dazhuo
    Ma, Xiaojuan
    MEDICINE, 2024, 103 (51)
  • [27] Repurposing Antihypertensive and Statin Medications for Spinal Pain: A Mendelian Randomization Study (vol 48, pg 1568, 2023)
    Suri, P.
    Elgaeva, E. E.
    Williams, F. M. K.
    SPINE, 2024, 49 (04) : E49 - E49
  • [28] Genetic proxies for antihypertensive drugs and mental disorders: Mendelian randomization study in European and East Asian populations
    Fan, Bohan
    Zhao, Jie V.
    BMC MEDICINE, 2024, 22 (01)
  • [29] Genetic proxies for antihypertensive drugs and mental disorders: Mendelian randomization study in European and East Asian populations
    Bohan Fan
    Jie V. Zhao
    BMC Medicine, 22
  • [30] Using Mendelian randomization study to assess the renal effects of antihypertensive drugs
    Zhao, Jie V.
    Schooling, C. Mary
    BMC MEDICINE, 2021, 19 (01)